Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated With GBA Mutations

Some people with Parkinson’s disease have changes (mutations) in a gene called GBA, which affects how a protein called GCase works. This protein helps keep cells in the brain healthy. When GCase doesn’t work properly, it can lead to faster disease progression. Unfortunately, there are currently no approved treatments that target this problem directly. Up to 15% of people with Parkinson’s have GBA-related Parkinson’s (known as PD-GBA), making this an important focus for research. A New Treatment in Development: CAP-003 A company called Capsida Biotherapeutics is developing a potential new treatment called CAP-003 to help people with PD-GBA. This treatment is designed to increase GCase activity in the brain, which could help slow or possibly stop the progression of the disease. In animal studies, just one IV dose of CAP-003 helped boost GCase activity in key parts of the brain by more than 30%—a level scientists believe may be enough to restore normal function. These studies also showed that the treatment was well tolerated and safe, with no harmful side effects seen. Capsida plans to begin a Phase 1/2 clinical trial this year, and they expect to start treating the first patient by fall. If successful, this could represent an important step forward in treating PD-GBA. Understanding PD-GBA The GBA gene provides instructions for making the GCase enzyme. When this enzyme doesn’t work well, waste builds up in brain cells and can lead to damage. People with PD-GBA typically have about 30% less GCase activity than those without the condition. Because current treatments don’t fix this enzyme issue, scientists have been trying new approaches—but many past attempts haven't been effective or have required invasive brain procedures. CAP-003 aims to deliver treatment through a simple IV, avoiding the need for more invasive methods. Who is Capsida Biotherapeutics? Capsida Biotherapeutics is a research company working on advanced gene therapies for brain and nervous system diseases. Their goal is to create treatments that do more than just manage symptoms—they aim to change the course of the disease.